Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 451 - 500 out of 9,399

Document Document Title
WO/2019/114674A1
The present application relates to a method for prepare a Cangrelor tetrasodium salt, comprising: using N-[2-(methylthio)ethyl]-2-[(3,3,3-trifluoropropyl)sulfonyl]a denosine as a raw material to undergo two steps of reaction to obtain a ...  
WO/2019/113462A1
This disclosure relates to certain N4-hydroxycytidine derivatives, pharmaceutical compositions, and methods related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of viral infections, such as East...  
WO/2019/110734A1
The present invention relates to novel spirobicyclic analogues of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention fu...  
WO/2019/112485A1
The invention relates to the field of molecular biology, biotechnology and molecular diagnostics. The invention can be used in the development and optimisation of PCR and RT-PCR systems used for detecting nucleic acids, inter alia, for d...  
WO/2019/109560A1
Provided is a method for extracting adenosine triphosphate from an adenosine triphosphate solution. The method is executed by using a heterocyclic compound, and the heterocyclic compound is a compound represented by formula (1), or a ste...  
WO/2019/110991A1
The present invention relates to compounds comprising a salt of a diphosphate phosphoramidate of a nucleoside drug, e.g. clofarabine. The compounds are useful in the treatment of cancer, e.g. leukemia.  
WO/2019/112567A1
This invention provides protease activity screening matrices that contain a solid support conjugated to a substrate moiety that can be specifically cleaved by a specific protease. The invention also provides methods for utilizing the pro...  
WO/2019/105388A1
The present invention relates to a new crystal form of compound I and a preparation method therefor, a pharmaceutical composition comprising the crystal form, and a use of the crystal form in preparing an A3 adenosine receptor agonist an...  
WO/2019/105421A1
The present invention relates to a nucleoside analogue having the structure of the following formula, a method for preparing the nucleoside analogue, and an application of the nucleoside analogue in nucleic acid sequencing, etc.  
WO/2019/108875A1
Provided herein are methods and compositions related to treating and/or preventing glaucoma in a subject by administering to the subject (e.g., orally administering to the subject) a composition comprising nicotinamide riboside and/or pt...  
WO/2019/108878A1
Provided herein are methods and compositions related to treating and/or preventing obesity and/or conditions associated with obesity in a subject by administering to the subject (e.g., orally administering to the subject) a composition c...  
WO/2019/108873A1
Provided herein are methods and compositions related to treating and/or preventing multiple sclerosis in a subject by administering to the subject (e.g., orally administering to the subject) a composition comprising nicotinamide riboside...  
WO/2019/102034A1
The present invention provides for stable nucleotide reagents used for nucleic acid amplification by PCR and RT-PCR (Reverse Transcriptase-PCR) that comprises modified nucleoside triphosphates. The present invention also provides for met...  
WO/2019/103050A1
Provided is a compound that, after administration into an organism, rapidly binds to blood albumin, persistently circulates systemically, and efficiently accumulates in tumor tissue and then releases an active drug. The compound exhibits...  
WO/2019/097233A1
The invention relates to the use of an amine masked moiety in a method of enzymatic nucleic acid synthesis. The invention also relates to said amine masked moieties per se and a process for preparing nucleotide triphosphates comprising s...  
WO/2019/092546A1
The present invention relates to a process for the preparation of Cangrelor in salt form of formula (V) by preparation and subsequent hydrolysis of an intermediate of formula (IV). The process is characterised by the high yield and purit...  
WO/2019/088179A1
Provided are: a nucleoside that is more suitable for practical use such as an RNA medicine or the like; and the use of the nucleoside. For this purpose, provided is a nucleoside derivative represented by formula (1) or (2) or a salt ther...  
WO/2019/089417A1
Provided herein are methods and compositions related to treating and/or preventing cystic fibrosis in a subject by administering to the subject (e.g., orally administering to the subject) a composition comprising nicotinamide riboside an...  
WO/2019/080724A1
Disclosed are a nucleoside phosphate compound, a pharmaceutical composition comprising same, and a preparation method therefor and the use thereof. Such a compound can be successfully metabolized within liver cells, and can produce an ac...  
WO/2019/079686A1
Provided herein are methods and compositions related to treating and/or preventing diseases or disorder associated with cytoplasmic accumulation of TDP-43 by administering to the subject (e.g., orally administering to the subject) a comp...  
WO/2019/079656A1
The present disclosure provides method and products for the selective enrichment of one population of DNA in a mixed sample comprising multiple populations of DNA. In some embodiments, the mixed sample comprises one or more populations o...  
WO/2019/076633A1
The present invention relates to novel nucleoside analogues and compositions containing said nucleoside analogues. Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of u...  
WO/2019/071474A1
The present invention relates to the field of nucleotide sequencing. Specifically, the invention relates to a modified nucleoside or nucleotide, wherein the 3'-OH of said modified nucleoside or said nucleotide is reversibly blocked, and ...  
WO/2019/075045A1
The present disclosure relates to compounds of formula I, which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.  
WO/2019/072005A1
The present invention relates to an azacitidine disaccharide impurity, a preparation method therefor and use thereof. A compound of formula III is obtained by reacting a compound represented by formula IV as a start raw material with a t...  
WO/2019/069297A2
Activity-based probes that can be used to selectively identify and characterize enzymes that are involved in different phases of xenobiotic metabolism in a host and its microbiota population(s) are described. The activity-based probes de...  
WO/2019/060740A1
Cytidine nucleoside analogues of Formula I, wherein the variables are as described herein, in combination with uridine nucleoside analogues of Formula II, wherein the variables are as described herein, produce a synergistic effect on the...  
WO/2019/060692A1
The present disclosure relates to crystalline morphic forms of 4-amino-7-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl)-2-methyl-7H-pyrrolo[2,3-d]pyrimidine-5 -carboxamide. The morphic form can be a stable hemihydra...  
WO/2019/053696A1
Disclosed herein are compounds of the Formula (I) and pharmaceutically acceptable salts thereof: (I) where the variables in Formula (I) are described herein. Methods of synthesizing such compounds and methods of using them to treat disea...  
WO/2019/052359A1
The aim of the present invention is to provide a compound containing a diheterocyclic ribavirin analog, a stereoisomer, a prodrug, a pharmaceutically acceptable salt, a compound salt and/or a solvated compound with structural general for...  
WO/2019/053609A1
The present invention describes W-position modified cytidine nucleotides of formula (I). Provided herein are methods of chemical synthesis of ΛΡ-modified cytidine nucleoside triphosphates and their applications as well as uses of the c...  
WO/2019/053659A1
The present disclosure relates to compounds and compositions containing 5'-phosphoramidite nucleoside monomers of formulae (I) and (II), and methods of making and use, wherein the substituents are as defined in the appended claims.  
WO/2019/053476A1
The present invention relates to a process for the preparation of floxuridine, said process comprising reacting a compound of Formula la with a compound of Formula lla in the presence of an acid Al to provide a compound of Formula Ilia i...  
WO/2019/042888A1
Disclosed is the use of perfluorinated nucleic acids and perfluorinated peptides as compounds with excellent properties. Surprisingly, it has been shown that compounds of nucleic acids and peptides with short-chain perfluorocarbons havin...  
WO/2019/043177A1
The present invention relates to 2'-spirothietane nucleosides, and the phosphates and the prodrugs thereof, and the pharmaceutically acceptable salts and solvates thereof, and the use of such compounds as a medicament, in particular in t...  
WO/2019/040418A1
Compounds and methods for treating viral infections and reducing viral multiplication, including flaviviruses. Provided is a derivative of a compound or a pharmaceutical salt thereof, wherein the compound comprises a 3',4-didehydroribose.  
WO/2019/036225A1
Diaryl-azo derivatives are efficient fluorescence quenchers as well as nucleic acid duplex-stabilizing agents and are useful in oligonucleotide conjugates and probes. The oligonucleotide-quencher conjugates may be used in detection metho...  
WO/2019/032859A1
The disclosure is directed to compounds of Formula (I). Pharmaceutical compositions comprising compounds of Formula (I), as well as methods of their use and preparation, are also described.  
WO/2019/032411A1
The invention provides potent anti-cancer methods and compositions that employ novel glycome compounds exemplified by glyco-benzaldehydes that disrupt anaerobic respiration and trigger apoptosis in cancer cells. Additionally, the inventi...  
WO/2019/025600A1
The present invention relates to a hydrate of sofosbuvir, more precisely to a monohydrate of sofosbuvir, and to a process for its preparation. Furthermore, the invention relates to a pharmaceutical composition comprising the sofosbuvir h...  
WO/2019/027920A1
Crystalline and amorphous forms of ethyl ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihyd rofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl)-L-alaninate (GS-9131), the vanillate, phosphate and xinafoate salts as well as the phospha...  
WO/2019/023748A1
The present invention relates to a method of increasing fertility, or reducing rate of decline in fertility, or restoring fertility, of a female subject, comprising administering to the subject an effective amount of an agent which eleva...  
WO/2019/023459A1
The present invention is directed to compounds of the formulae I, II and III as shown below (I) (II) (III) wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the inven...  
WO/2019/022158A1
Provided are a compound represented by formula I that can be used in nucleic acid photoreaction techniques, and a photoreactive crosslinking agent comprising the compound.  
WO/2019/012080A1
The present disclosure relates to new nucleotide and oligonucleotide compounds and their use in nucleic acid sequencing applications. The compounds have formula (I) wherein B is a nucleoside base; and Fl is a fluorophore attached through...  
WO/2019/012328A1
The present invention relates to combination therapies of a cytarabine conjugate and one or more anti-neoplastic agents for inhibiting cancer cell growth. In particular, the present invention relates to a conjugate of cytarabine and aspa...  
WO/2018/041942A9
Embodiments of the invention are directed to new polymer linked multimeric guanosine-3', 5'-cyclic monophosphate (cGMP) analogues that modulate the cGMP-signaling system, preferably having activating properties, and more preferably being...  
WO/2019/005898A1
Compositions and method are therefore disclosed for treating chronic obstructive pulmonary disease (COPD) and/or pulmonary fibrosis (PF). In particular, disclosed a composition that contains one, two, or more cytidine diphosphate (CDP)-c...  
WO/2019/006455A1
Disclosed are P-stereogenic groups that may be used in the synthesis of compounds including stereochemically enriched P-stereogenic phosphorothioates. P-stereogenic groups may be provided in nucleoside phosphoramidites including a sugar ...  
WO/2019/005901A1
Compositions and method are therefore disclosed for treating asthma. In particular, disclosed a composition that contains one, two, or more cytidine diphosphate (CDP)-conjugated phospholipid precursors selected from the group consisting ...  

Matches 451 - 500 out of 9,399